Project description
A safer blood vessel imaging tool
Diagnosis and monitoring of cardiovascular diseases entail the X-ray imaging of blood vessels through a method known as angiography. However, angiography can have detrimental side effects on both patients and staff performing the procedure, such as radiation-induced cancer. Additionally, patients also face the risk of potential kidney injury. The EU-funded KMIT-ACC project has developed a novel angiography imaging technology that limits the dose of X-ray and iodinated contrast media while offering enhanced image quality. Implementation of the KMIT-ACC dose management and image-processing tool in the clinic is expected to reduce the negative impact of conventional angiography with important socioeconomic benefits.
Objective
Cardiovascular disorders are the number one health problem in the high-income societies. X-ray imaging of blood vessels is widely used in diagnosis and treatment of cardiovascular conditions, but it has several drawbacks: Image quality is sometimes insufficient; Applied Iodinated Contrast Media (ICM) may induce kidney injuries; X-ray exposure of patient and staff may cause cancer. Image quality improvement and radical reduction of ICM/X-ray dose are an unmet need. Our team has developed Digital Variance Angiography imaging and implemented it in a software, the Kinepict Medical Imaging Tool (KMIT). This ground-breaking patented technology can change the currently used angiography methods, improving image quality (3-10 times higher signal-to-noise ratio) and providing a dose management solution to reduce X-ray and ICM dose at least by 75% and 50%, respectively. Using the KMIT offers several advantages: a)Risk of angiography procedures is reduced dramatically for both patient and staff. b)The society benefits from smaller morbidity and mortality of cancer and kidney injury c)Hospitals save 220,000 €/year on direct costs d)Health care system expenses are reduced by around 300,000 €/year/licencing hospital e)Total savings might reach the 300 M€/year in the EU (assuming a 10 % market penetration. Our customers are healthcare institutions doing vascular interventions; the users of our product are vascular surgeons and interventional radiologists. Our total addressable market size in Europe and USA is around €300 M. Our goal is to revolutionize X-ray angiography by introducing a dose management and image processing tool. The current proposal is organized around the following objectives: a) clinical validation of our technology for new indications, b) organization of a reference laboratory network, c) software and hardware optimization to reach TRL 9 level and d) baseline commercial activities.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences computer and information sciences software
- natural sciences biological sciences cell biology cell metabolism
- medical and health sciences clinical medicine cardiology cardiovascular diseases
- engineering and technology medical engineering diagnostic imaging
- social sciences economics and business business and management commerce
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
2092 Budakeszi
Hungary
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.